Sökning: onr:"swepub:oai:prod.swepub.kib.ki.se:237106995" >
Neutralizing Carbap...
Neutralizing Carbapenem Resistance by Co-Administering Meropenem with Novel β-Lactam-Metallo-β-Lactamase Inhibitors
- Artikel/kapitelEngelska2023
Förlag, utgivningsår, omfång ...
Nummerbeteckningar
-
LIBRIS-ID:oai:prod.swepub.kib.ki.se:237106995
-
http://kipublications.ki.se/Default.aspx?queryparsed=id:237106995URI
-
https://doi.org/10.3390/antibiotics12040633DOI
-
http://kipublications.ki.se/Default.aspx?queryparsed=id:152766286URI
Kompletterande språkuppgifter
-
Språk:engelska
-
Sammanfattning på:engelska
Ingår i deldatabas
Klassifikation
-
Ämneskategori:ref swepub-contenttype
-
Ämneskategori:art swepub-publicationtype
Anmärkningar
-
gratis
-
Virulent Enterobacterale strains expressing serine and metallo-β-lactamases (MBL) genes have emerged responsible for conferring resistance to hard-to-treat infectious diseases. One strategy that exists is to develop β-lactamase inhibitors to counter this resistance. Currently, serine β-lactamase inhibitors (SBLIs) are in therapeutic use. However, an urgent global need for clinical metallo-β-lactamase inhibitors (MBLIs) has become dire. To address this problem, this study evaluated BP2, a novel beta-lactam-derived β-lactamase inhibitor, co-administered with meropenem. According to the antimicrobial susceptibility results, BP2 potentiates the synergistic activity of meropenem to a minimum inhibitory concentration (MIC) of ≤1 mg/L. In addition, BP2 is bactericidal over 24 h and safe to administer at the selected concentrations. Enzyme inhibition kinetics showed that BP2 had an apparent inhibitory constant (Kiapp) of 35.3 µM and 30.9 µM against New Delhi Metallo-β-lactamase (NDM-1) and Verona Integron-encoded Metallo-β-lactamase (VIM-2), respectively. BP2 did not interact with glyoxylase II enzyme up to 500 µM, indicating specific (MBL) binding. In a murine infection model, BP2 co-administered with meropenem was efficacious, observed by the >3 log10 reduction in K. pneumoniae NDM cfu/thigh. Given the promising pre-clinical results, BP2 is a suitable candidate for further research and development as an (MBLI).
Biuppslag (personer, institutioner, konferenser, titlar ...)
-
Girdhari, L
(författare)
-
Shungube, M
(författare)
-
Gouws, AC
(författare)
-
Peters, BK
(författare)
-
Rajbongshi, KK
(författare)
-
Baijnath, S
(författare)
-
Mdanda, S
(författare)
-
Ntombela, T
(författare)
-
Arumugam, T
(författare)
-
Bester, LA
(författare)
-
Singh, SD
(författare)
-
Chuturgoon, A
(författare)
-
Arvidsson, PIKarolinska Institutet
(författare)
-
Maguire, GEM
(författare)
-
Kruger, HG
(författare)
-
Govender, T
(författare)
-
Naicker, T
(författare)
-
Karolinska Institutet
(creator_code:org_t)
Sammanhörande titlar
-
Ingår i:Antibiotics (Basel, Switzerland): MDPI AG12:42079-6382
Internetlänk
Hitta via bibliotek
Till lärosätets databas
- Av författaren/redakt...
-
Reddy, N
-
Girdhari, L
-
Shungube, M
-
Gouws, AC
-
Peters, BK
-
Rajbongshi, KK
-
visa fler...
-
Baijnath, S
-
Mdanda, S
-
Ntombela, T
-
Arumugam, T
-
Bester, LA
-
Singh, SD
-
Chuturgoon, A
-
Arvidsson, PI
-
Maguire, GEM
-
Kruger, HG
-
Govender, T
-
Naicker, T
-
visa färre...
- Artiklar i publikationen
-
Antibiotics (Bas ...
- Av lärosätet
-
Karolinska Institutet